HIBISKUS BIOPHARMA
Hibiskus Biopharma is an early-stage pharmaceutical venture pursuing the development of small-molecule cancer therapy, TIR-199. TIR-199 is a potent proteasome inhibitor from the syrbactin natural product family. It was discovered by the company’s founders, Profs. Pirrung and Bachmann of the University of California, Riverside (UCR), and Michigan State University (MSU), respectively. UCR holds multiple patents related to the production of TIR-199 and its use in treating cancers and immune disorders.
HIBISKUS BIOPHARMA
Industry:
Biotechnology Health Care Medical Pharmaceutical Therapeutics
Founded:
2017-01-01
Address:
Kalamazoo, Michigan, United States
Country:
United States
Website Url:
http://www.hibiskusbio.com
Status:
Active
Technology used in webpage:
Domain Not Resolving Gravatar Profiles
Similar Organizations
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Biohelix
Biohelix is to improve the quality of healthcare through the development of simple molecular diagnostic tests.
Mistral Pharma
Mistral Pharma, Inc. is a development stage pharmaceutical product development and drug delivery company.
Nivalis Therapeutics
Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.
Pacylex
Pacylex Pharmaceuticals develops a precision medicine solution for multiple common cancers.
Founder
More informations about "Hibiskus Biopharma"
Hibiskus Biopharma - Crunchbase Company Profile
Hibiskus Biopharma is an early-stage pharmaceutical venture pursuing the development of small-molecule cancer therapy, TIR-199. TIR-199 is a potent …See details»
Hibiskus BioPharma 2025 Company Profile: Valuation, …
Hibiskus BioPharma General Information Description. Operator of a pharmaceutical company intended for the development of novel small-molecule cancer therapy. The company develops small molecule proteasome inhibitors …See details»
Hibiskus BioPharma - Products, Competitors, Financials, Employees ...
Hibiskus BioPharma is an early-stage pharmaceutical venture pursuing the development of a novel small-molecule cancer therapy, TIR-199. On September 3rd, 2020, Hibiskus BioPharma …See details»
Hibiskus BioPharma - Ownership and Business Overview - Mergr
Sep 3, 2020 Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2020.The largest life science acquisition in 2020 was Alexion Pharmaceuticals - which was …See details»
Hibiskus Biopharma - Funding, Financials, Valuation & Investors
Organization. Hibiskus Biopharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Funding Rounds 1. Investors 1. …See details»
Hibiskus Biopharma’s Competitors, Revenue, Number of ... - Owler
Hibiskus Biopharma’s Profile, Revenue and Employees. Hibiskus is a biotechnology company that develops and commercializes novel small-molecule therapeutics for the treatment of cancer. …See details»
Hibiskus Biopharma, Inc. - - Overview, Competitors, and ... - Apollo.io
Hibiskus is a biotechnology company that develops and commercializes novel small-molecule therapeutics for the treatment of cancer.See details»
Hibiskus Biopharma acquired by Lodo Therapeutics - Crunchbase
Mar 9, 2020 Acquired Organization: Hibiskus Biopharma Hibiskus Biopharma is an early-stage pharmaceutical venture pursuing the development of small-molecule cancer therapy. Acquiring …See details»
Hibiskus company information, funding & investors | Oslo startup …
Hibiskus, hibiskus biopharma, inc. – a biopharmaceutical company. Here you'll find information about their funding, investors and team.See details»
Hibiskus BioPharma-动脉网 - vbdata.cn
Hibiskus是一家早期制药企业，致力于开发新型小分子癌症疗法TIR-199。 TIR-199是一种来自Syrbactin天然产物家族的有效蛋白酶体抑制剂。它是由公司的创始人Profs。分别来自加利福 …See details»
Hibiskus Biopharma Reviews | Read Client Reviews of Hibiskus …
Read reviews of Hibiskus Biopharma. Write and share your personal story. Your experience will help others make the right buying decision.See details»
Hibiskus BioPharma DMF, CEP, Written Confirmations, FDF, Prices ...
Hibiskus aims to become the selective proteasome inhibitor company by targeting each of the 7 human proteasome catalytic ß subunits with its macrolactam drug candidates. While …See details»
Hibiscus BioVentures - LinkedIn
Hibiscus BioVentures | 774 followers on LinkedIn. Building patient-focused companies around transformative biotechnologies | Committed to significantly moving patient care forward by …See details»
Lodo Therapeutics Acquires Hibiskus BioPharma | WMed
Lodo Therapeutics Corp. (Lodo), a biotechnology company reinventing natural product drug discovery by applying its informatics-enabled technology platform to previously undruggable …See details»
Lodo Therapeutics Acquires Hibiskus BioPharma And Licenses …
NEW YORK, Sept. 3, 2020 /PRNewswire/ -- Lodo Therapeutics Corp. (Lodo), a biotechnology company reinventing natural product drug discovery by applying its informatics-enabled …See details»
Hibiscus BioVentures - Crunchbase Investor Profile & Investments
Hibiscus Bio is a Biotechnology and Pharmaceutical Industry-Specific consultancy focused on M&A and Corporate Development.See details»
Lodo Therapeutics Acquires Hibiskus BioPharma And Licenses …
Sep 10, 2020 Lodo Therapeutics Corp. (Lodo), a biotechnology company reinventing natural product drug discovery by applying its informatics-enabled technology platform to previously …See details»
Hibiscus BioVentures Partners with the Barbara Ann Karmanos …
Jan 5, 2022 ROCKVILLE, Md.--(BUSINESS WIRE)--Hibiscus BioVentures, a firm committed to building patient-focused companies around transformative technologies, today announced it …See details»
Hibiscus BioVentures - Contacts, Employees, Board Members, …
Hibiscus Bio is a Biotechnology and Pharmaceutical Industry-Specific consultancy focused on M&A and Corporate Development.See details»
Mayo Clinic, Hibiscus BioVentures and Innoforce announce …
Aug 31, 2022 ROCHESTER, Minn., and ROCKVILLE, Md. — Mayo Clinic, Hibiscus BioVentures (Hibiscus) and Innoforce announce the launch of Mayflower BioVentures, a cell and gene …See details»